Evidence map›Paper›PMID 27788264›Full record

ArticlePloS one2016

DRAQ5 and Eosin ('D&E') as an Analog to Hematoxylin and Eosin for Rapid Fluorescence Histology of Fresh Tissues.

Katherine N Elfer, Andrew B Sholl, Mei Wang, David B Tulman, Sree H Mandava, Benjamin R Lee, J Quincy Brown

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Assessing the Effects of a 3-Dimensional (3D) Pathology Tissue-Processing Workflow on Downstream Molecular Analyses.Laboratory investigation; a journal of technical methods and pathology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Engineering the future of 3D pathology.The journal of pathology. Clinical research · 2024
    Article
  11. Article
  12. Article
  13. An end-to-end workflow for non-destructive 3D pathology.bioRxiv : the preprint server for biology · 2023
    Article
  14. Review
  15. Review
  16. Article
  17. Tissue harvest with a laser microbiopsy.Journal of biomedical optics · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Katherine N ElferDept. of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Andrew B ShollDept. of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Mei WangDept. of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
David B TulmanDept. of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Sree H MandavaDept. of Urology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Benjamin R LeeDept. of Urology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
J Quincy BrownDept. of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Tulane University · US

Funding

Improving biospecimen quality by verifying adequacy at the point-of-acquisition with ex vivo structured illumination microscopyR33CA196457 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI BROWN, JONATHAN QUINCY · 2015 to 2017
$946k
A Fluorescence Histology System for In Vivo Breast Tumor Margin AssessmentR21CA159936 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI BROWN, JONATHAN QUINCY · 2011 to 2012
$448k
NCI NIH HHS R21 CA159936NCI NIH HHS R33 CA196457
6 · The paper itself

Abstract

Real-time on-site histopathology review of biopsy tissues at the point-of-procedure has great potential for significant clinical value and improved patient care. For instance, on-site review can aid in rapid screening of diagnostic biopsies to reduce false-negative results, or in quantitative assessment of biospecimen quality to increase the efficacy of downstream laboratory and histopathology analysis. However, the only currently available rapid pathology method, frozen section analysis (FSA), is too time- and labor-intensive for use in screening large quantities of biopsy tissues and is too destructive for maximum tissue conservation in multiple small needle core biopsies. In this work we demonstrate the spectrally-compatible combination of the nuclear stain DRAQ5 and the anionic counterstain eosin as a dual-component fluorescent staining analog to hematoxylin and eosin intended for use on fresh, unsectioned tissues. Combined with optical sectioning fluorescence microscopy and pseudo-coloring algorithms, DRAQ5 and eosin ("D&E") enables very fast, non-destructive psuedohistological imaging of tissues at the point-of-acquisition with minimal tissue handling and processing. D&E was validated against H&E on a one-to-one basis on formalin-fixed paraffin-embedded and frozen section tissues of various human organs using standard epi-fluorescence microscopy, demonstrating high fidelity of the staining mechanism as an H&E analog. The method was then applied to fresh, whole 18G renal needle core biopsies and large needle core prostate biospecimen biopsies using fluorescence structured illumination optical sectioning microscopy. We demonstrate the ability to obtain high-resolution histology-like images of unsectioned, fresh tissues similar to subsequent H&E staining of the tissue. The application of D&E does not interfere with subsequent standard-of-care H&E staining and imaging, preserving the integrity of the tissue for thorough downstream analysis. These results indicate that this dual-stain pseudocoloring method could provide a real-time histology-like image at the time of acquisition and valuable objective tissue analysis for the clinician at the time of service.

Indexed as

AnthraquinonesBiopsyEosine Yellowish-(YS)FluorescenceHematoxylinHumans1,5-bis((2-(methylamino)ethyl)amino)-4,8-dihydroxyanthracene-9,10-dioneAnthraquinonesEosine Yellowish-(YS)Hematoxylin

Identifiers

PMID27788264
PMCPMC5082869
OpenAlexW2540860426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.